SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilder Biotech Report
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: azluke who wrote (14)11/30/2001 7:15:10 PM
From: Cosmo Daisey  Read Replies (1) of 25
 
azluke,
I own both also. I have some friends at the Harvard Bio lab and they were all over VRTX @ $50. when it was pulling back. There is a connection between the CEO of VRTX and the head of the Harvard lab, classmates or something. These guys shoot the load in one shot so they probably aren't adding @ 25 which would seem to be a good idea if they like the stock. They just buy the stock and hold it through ups and downs.
NGEN is definately the leader in their field but they need FDA approval for some tests to get roling.
Cosmo
PS misspelled words are intentional
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News